Cancer statistics, 2023

CA A Cancer Journal for Clinicians, Год журнала: 2023, Номер 73(1), С. 17 - 48

Опубликована: Янв. 1, 2023

Each year, the American Cancer Society estimates numbers of new cancer cases and deaths in United States compiles most recent data on population-based occurrence outcomes using incidence collected by central registries mortality National Center for Health Statistics. In 2023, 1,958,310 609,820 are projected to occur States. increased prostate 3% annually from 2014 through 2019 after two decades decline, translating an additional 99,000 cases; otherwise, however, trends were more favorable men compared women. For example, lung women decreased at one half pace (1.1% vs. 2.6% annually) 2015 2019, breast uterine corpus cancers continued increase, as did liver melanoma, both which stabilized aged 50 years older declined younger men. However, a 65% drop cervical during 2012 among their early 20s, first cohort receive human papillomavirus vaccine, foreshadows steep reductions burden papillomavirus-associated cancers, majority Despite pandemic, contrast with other leading causes death, death rate decline 2020 (by 1.5%), contributing 33% overall reduction since 1991 estimated 3.8 million averted. This progress increasingly reflects advances treatment, particularly evident rapid declines (approximately 2% 2016 2020) leukemia, kidney cancer, despite stable/increasing incidence, accelerated cancer. summary, although rates continue future may be attenuated rising breast, prostate, also happen have largest racial disparities mortality.

Язык: Английский

---

Cancer treatment and survivorship statistics, 2022

CA A Cancer Journal for Clinicians, Год журнала: 2022, Номер 72(5), С. 409 - 436

Опубликована: Июнь 23, 2022

The number of cancer survivors continues to increase in the United States due growth and aging population as well advances early detection treatment. To assist public health community better serving these individuals, American Cancer Society National Institute collaborate triennially estimate prevalence using incidence survival data from Surveillance, Epidemiology, End Results registries, vital statistics Centers for Disease Control Prevention's Center Health Statistics, projections US Census Bureau. Current treatment patterns based on information Database are presented most prevalent types by race, cancer-related treatment-related side-effects also briefly described. More than 18 million Americans (8.3 males 9.7 females) with a history were alive January 1, 2022. 3 cancers prostate (3,523,230), melanoma skin (760,640), colon rectum (726,450) among breast (4,055,770), uterine corpus (891,560), thyroid (823,800) females. one-half (53%) diagnosed within past 10 years, two-thirds (67%) aged 65 years or older. One largest racial disparities is rectal cancer, which 41% Black patients stage I disease receive proctectomy proctocolectomy compared 66% White patients. Surgical receipt substantially lower non-small cell lung 49% stages I-II 16% III versus 55% 22% patients, respectively. These exacerbated fact that continue be less likely cancers, some female (53% vs 68%) endometrial (59% 73%). Although there growing tools can caregivers, clinicians navigating various phases survivorship, further evidence-based strategies equitable access available resources needed mitigate communities color optimize care people cancer. CA J Clin. 2022;72:409-436.

Язык: Английский

---

Cancer statistics in China and United States, 2022: profiles, trends, and determinants

Chinese Medical Journal, Год журнала: 2022, Номер 135(5), С. 584 - 590

Опубликована: Фев. 9, 2022

Abstract Background: The cancer burden in the United States of America (USA) has decreased gradually. However, China is experiencing a transition its profiles, with greater incidence cancers that were previously more common USA. This study compared latest trends, and determinants between Methods: was comparative using open-source data. Cancer cases deaths 2022 calculated estimates from GLOBOCAN 2020 population Nations. Trends mortality rates USA used data Surveillance, Epidemiology, End Results program National Center for Health Statistics. Chinese obtained registry reports. Data Global Burden Disease 2019 decomposition method to express as product four determinant factors. Results: In 2022, there will be approximately 4,820,000 2,370,000 new cases, 3,210,000 640,000 USA, respectively. most are lung breast leading cause death both. Age-standardized colorectal have significantly recently, but liver increased slightly. Rates stomach, liver, esophageal gradually China, whole population, prostate men, other seven types women. Increases adult size aging major incremental deaths, case-fatality contributed reduced both countries. Conclusions: decreasing esophagus, increasing lung, colorectum, breast, prostate, mean profiles converging. Population growing burden. Progress prevention care measures actively respond aging, may help reduce

Язык: Английский

---

Breast Cancer Statistics, 2022

CA A Cancer Journal for Clinicians, Год журнала: 2022, Номер 72(6), С. 524 - 541

Опубликована: Окт. 3, 2022

Abstract This article is the American Cancer Society’s update on female breast cancer statistics in United States, including population‐based data incidence, mortality, survival, and mammography screening. Breast incidence rates have risen most of past four decades; during recent years (2010–2019), rate increased by 0.5% annually, largely driven localized‐stage hormone receptor‐positive disease. In contrast, mortality declined steadily since their peak 1989, albeit at a slower pace (1.3% annually from 2011 to 2020) than previous decade (1.9% 2002 2011). total, death dropped 43% 1989–2020, translating 460,000 fewer deaths that time. The similarly for women all racial/ethnic groups except Indians/Alaska Natives, among whom were stable. However, despite lower Black versus White (127.8 vs. 133.7 per 100,000), racial disparity remained unwavering, with 40% higher overall (27.6 19.7 100,000 2016–2020) two‐fold adult younger 50 (12.1 6.5 100,000). lowest 5‐year relative survival any group every molecular subtype stage disease (except I), largest Black–White gaps absolute terms receptor‐positive/human epidermal growth factor receptor 2‐negative (88% 96%), receptor‐negative/human 2‐positive (78% 86%), III (64% 77%). Progress against could be accelerated mitigating disparities through access high‐quality screening treatment via nationwide Medicaid expansion partnerships between community stakeholders, advocacy organizations, health systems.

Язык: Английский

---

Hepatocellular carcinoma

The Lancet, Год журнала: 2022, Номер 400(10360), С. 1345 - 1362

Опубликована: Сен. 6, 2022

Язык: Английский

---

Non–Small Cell Lung Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology

Journal of the National Comprehensive Cancer Network, Год журнала: 2022, Номер 20(5), С. 497 - 530

Опубликована: Май 1, 2022

NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Non-Small Cell Lung Cancer (NSCLC) provide recommended management patients with NSCLC, including diagnosis, primary treatment, surveillance relapse, and subsequent treatment. Patients metastatic lung cancer who are eligible targeted therapies or immunotherapies now surviving longer. This selection from the NSCLC focuses on actionable mutations.

Язык: Английский

---

Soft Tissue Sarcoma, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology

Journal of the National Comprehensive Cancer Network, Год журнала: 2022, Номер 20(7), С. 815 - 833

Опубликована: Июль 1, 2022

Soft tissue sarcomas (STS) are rare malignancies of mesenchymal cell origin that display a heterogenous mix clinical and pathologic characteristics. STS can develop from fat, muscle, nerves, blood vessels, other connective tissues. The evaluation treatment patients with requires multidisciplinary team demonstrated expertise in the management these tumors. complete NCCN Clinical Practice Guidelines Oncology (NCCN Guidelines) for Tissue Sarcoma provide recommendations diagnosis, evaluation, extremity/superficial trunk/head neck STS, as well retroperitoneal/intra-abdominal desmoid tumors, rhabdomyosarcoma. This portion discusses general principles diagnosis outlines recommendations, reviews evidence to support guidelines recommendations.

Язык: Английский

---

CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2015–2019

Neuro-Oncology, Год журнала: 2022, Номер 24(Supplement_5), С. v1 - v95

Опубликована: Окт. 5, 2022

Abstract The Central Brain Tumor Registry of the United States (CBTRUS), in collaboration with Centers for Disease Control and Prevention National Cancer Institute, is largest population-based registry focused exclusively on primary brain other central nervous system (CNS) tumors (US) represents entire US population. This report contains most up-to-date data available supersedes all previous reports terms completeness accuracy. All rates are age-adjusted using 2000 standard population presented per 100,000 average annual incidence rate (AAAIR) malignant non-malignant CNS was 24.71 (malignant AAAIR=7.02 AAAIR=17.69). overall higher females compared to males (27.62 versus 21.60 100,000) non-Hispanic persons Hispanic (25.09 22.95 100,000). commonly occurring histopathology glioblastoma (14.2% 50.1% tumors), common meningioma (39.7% 55.4% tumors). Glioblastoma more males, meningiomas were females. In children adolescents (ages 0-19 years), 6.20 An estimated 93,470 new cases expected be diagnosed 2022 (26,670 66,806 non-malignant). There 84,264 deaths attributed between 2015 2019. an mortality 4.41 16,853 year. five-year relative survival following diagnosis a tumor 35.7%, while 91.8%.

Язык: Английский

---

Breast Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology

Journal of the National Comprehensive Cancer Network, Год журнала: 2022, Номер 20(6), С. 691 - 722

Опубликована: Июнь 1, 2022

The therapeutic options for patients with noninvasive or invasive breast cancer are complex and varied. These NCCN Clinical Practice Guidelines Breast Cancer include recommendations clinical management of carcinoma in situ, cancer, Paget disease, phyllodes tumor, inflammatory during pregnancy. content featured this issue focuses on the overall ductal situ workup locoregional early stage cancer. For full version Cancer, visit NCCN.org .

Язык: Английский

---

The global burden of lung cancer: current status and future trends

Nature Reviews Clinical Oncology, Год журнала: 2023, Номер 20(9), С. 624 - 639

Опубликована: Июль 21, 2023

Язык: Английский

---